Regeneron Pharmaceuticals Conference Call Summary Company Overview - **Company**: Regeneron Pharmaceuticals (NasdaqGS:REGN) - **Date**: March 11, 2026 - **Key Speakers**: Marion McCourt (Executive Vice President of Commercial), Ryan Crowe (Senior Vice President of Investor Relations and Strategy) Core Industry Insights Commercial Performance - **EYLEA HD**: - Q4 sales reached **$506 million**, marking a **66% year-over-year growth** [11] - Label enhancements in November included weekly dosing and RVO indication [11] - **DUPIXENT**: - Q4 sales totaled **$4.9 billion**, a **32% increase** year-over-year [12] - Strong performance across all indications, with significant growth in asthma and new launches in COPD and CSU [13][14] - **Libtayo**: - Generated **$525 million** in Q4, a **13% year-over-year increase** [12] Market Dynamics - **DUPIXENT** remains the leading product in its category, with significant under-penetration in atopic dermatitis [13] - EYLEA is facing competition from biosimilars, leading to expected declines in its sales, although EYLEA HD is showing high single-digit growth [16][17] - The company anticipates additional biosimilar competition for EYLEA in the second half of the year [17] Pipeline Developments New Product Launches - **Lynozyfic**: Recently launched for later-line patients, showing positive uptake [14] - **Cemdisiran**: Expected approval for generalized myasthenia gravis (MG) by early next year, with a potential market size of **$5 billion** today, projected to reach **$10 billion** by 2030 [47] - **Geographic Atrophy (GA)**: Combination therapy with cemdisiran and pozelimab is in development, with interim analysis expected by the end of 2026 [55] Strategic Partnerships - The alliance with **Sanofi** has been crucial for the success of DUPIXENT, with **1.4 million patients** currently on the medication [26] - Discussions are ongoing regarding the potential extension of the alliance and leveraging both companies' pipelines for future growth [27][28] Financial Strategy - Regeneron emphasizes a disciplined approach to capital allocation and is open to M&A opportunities that align with its therapeutic focus [21][22] - The company is building out its commercial infrastructure to support new product launches and expand its therapeutic areas [22][40] Risks and Considerations - The company acknowledges the risks associated with forward-looking statements and the potential impact of biosimilar competition on EYLEA sales [3][4] - There is a focus on ensuring the safety and efficacy of new products in the market, particularly in the context of competitive pressures [36] Conclusion - Regeneron Pharmaceuticals is positioned for continued growth with a strong commercial performance in key products like DUPIXENT and EYLEA HD, while also expanding its pipeline with promising new therapies. The strategic alliance with Sanofi remains a cornerstone of its success, and the company is actively exploring opportunities for future growth through M&A and new product launches.

Summary of Regenxbio FY Conference Call (March 10, 2026) Company Overview - **Company**: Regenxbio (NasdaqGS: RGNX) - **Key Products**: DUPIXENT, EYLEA, linvoseltamab, fianlimab, LIBTAYO Core Industry Insights DUPIXENT - **Sales Performance**: Achieved $17.8 billion in sales for the previous year, representing a 32% year-over-year growth [8][9] - **Market Position**: Positioned well with growth anticipated across all 9 FDA-approved indications, including recent launches for chronic spontaneous urticaria (CSU) and chronic obstructive pulmonary disease (COPD) [3][9] - **Launch Success**: Strong start for CSU and significant unmet need addressed by COPD, with robust payer coverage and enthusiasm from pulmonologists [10][11] - **Life Cycle Management**: Plans for new long-acting formulations (Super Dupie) and other antibodies targeting IL-4 and IL-13 to sustain revenue against emerging competition [19][20][21] EYLEA - **Sales Growth**: Reported $506 million in sales for EYLEA HD, up 66% year-over-year [22] - **Product Enhancements**: Anticipation of prefilled syringe approval expected to enhance operational workflows in retinal clinics [22][23] - **Market Dynamics**: Expectation of double-digit sequential decline in EYLEA sales due to biosimilar competition, while transitioning patients to EYLEA HD [25][26] Linvoseltamab - **Market Opportunity**: Targeting a refractory patient population in fourth-line myeloma, with potential expansion into earlier lines of therapy [34][35] - **Patient Population**: Approximately 3,000-4,000 patients in the U.S. for the fourth-line setting, with aspirations to capture a larger share of the $30 billion market [35][36] Obesity Program - **Product Development**: Olatorepatide shows promising results with 19% weight loss in pivotal data from China, with plans for U.S. phase 3 studies [27][28] - **Combination Therapy**: Exploring co-formulation of alirocumab (Praluent) with olatorepatide to address dual needs of weight loss and LDL cholesterol reduction [29][30] Key Catalysts and Future Outlook - **Pipeline Readouts**: Anticipated interim readouts for geographic atrophy and PNH towards the end of the year, with pivotal data from Factor XI expected in the first half of next year [39][40] - **Competitive Landscape**: Monitoring competitor readouts for insights and potential impacts on Regenxbio's strategies [40] Additional Insights - **Regulatory Risks**: Forward-looking statements are subject to risks and uncertainties, with no obligation to update based on new information [5] - **Market Education**: Emerging competition in atopic dermatitis is seen as beneficial for DUPIXENT by increasing market education and awareness [17][18] This summary encapsulates the key points discussed during the conference call, highlighting Regenxbio's strategic positioning, product performance, and future opportunities within the biopharmaceutical industry.

Connect Biopharma Conference Call Summary Company Overview - Connect Biopharma is developing a next-generation IL-4 receptor alpha monoclonal antibody, referred to as a next-generation DUPIXENT, targeting atopic dermatitis and asthma [3][4] Core Insights and Arguments Product Development and Efficacy - The product has shown rapid onset of effect in chronic asthma studies, with significant improvements in FEV1 (lung function) observed in less than 24 hours [3] - Current treatments for acute exacerbations of asthma and COPD have not changed in over 30 years, relying on bronchodilators and prednisone, which only provide temporary stabilization [4] - Connect Biopharma is conducting studies to evaluate the efficacy of their drug, Rademikibart, in treating acute exacerbations in asthma and COPD patients, with top-line results expected mid-year [5][6] Unique Mechanism of Action - The drug binds differently to the IL-4 receptor compared to DUPIXENT, leading to a different safety and efficacy profile, including a modest decline in eosinophils, which is beneficial for targeted patients [7][8] - The drug enhances the effectiveness of beta-agonists, which are standard rescue medications for asthma and COPD, unlike DUPIXENT [9] Market Opportunity - There is a significant market opportunity in the acute treatment of asthma and COPD, with approximately 1 million asthma and 1.3 million COPD patients visiting emergency departments annually in the U.S. [19] - No new drugs have been developed for acute treatment in over 50 years, creating a "white space" for Connect Biopharma to dominate this market [19][22] Clinical Trial Design - The company is using a similar approach to the ABRA study for trial design, focusing on treatment failure as a primary endpoint, with an anticipated 50% failure rate for standard care [28] - Enrollment strategies include both acute care settings and pre-enrollment through pulmonologists to identify high-risk patients [30][33] Financial and Strategic Considerations - Payers are willing to reimburse biologics in the ER setting, with a price range of $600-$700 per dose, significantly lower than DUPIXENT's $3,800 per month [35][36] - The acute indication is expected to drive chronic utilization, with 75% of clinicians wanting to continue treatment with the same drug after acute administration [38] Partnership and Future Prospects - Connect Biopharma has a partnership with Simcere in China, with significant milestones and tiered royalties expected from their ongoing studies in atopic dermatitis and asthma [42][43] - The approval of the drug in China could provide substantial non-dilutive capital and support for further development in Western markets [44] Additional Insights - The company anticipates that the Phase III studies from China will provide supportive data for regulatory approval in Western markets, potentially reducing development costs and risks [44]

Regeneron Pharmaceuticals FY Conference Summary Company Overview - **Company**: Regeneron Pharmaceuticals (NasdaqGS:REGN) - **Event**: FY Conference held on March 04, 2026 Key Industry Insights - **Clinical Programs**: Regeneron is actively working on **50 clinical programs**, which are not fully reflected in the current valuation of the company [2][4] - **Earnings Growth**: Projected earnings could reach **$70 to $80** per share in the next two to three years, potentially leading to a share price exceeding **$1,000** if trading at historical multiples [4][5] Core Business Drivers - **EYLEA HD**: Transitioning from EYLEA 2 mg to EYLEA HD, with recent approvals for every-four-week dosing and RVO, which represents **20%** of the market opportunity [6][7] - **DUPIXENT**: Annualized revenue for DUPIXENT was just under **$5 billion** in Q4, with expectations for continued growth due to recent launches and expansions [7][8] - **Development Balance Repayment**: Expected repayment of approximately **$600 million** by mid-2026, leading to benefits in the second half of the year and beyond [8][9] Pipeline Developments - **Oncology Franchise**: Libtayo is expected to perform well following its launch in adjuvant CSCC, with a sizable market opportunity of **20,000 patients** in the U.S. and abroad [32] - **Cemdisiran**: Targeting myasthenia gravis with a potential launch in **2026**, and pivotal studies for PNH expected to read out by **2027** [36][37] - **Long-acting Products**: Development of long-acting IL-13 and IL-4 blockers, with plans to enter clinical trials soon [24][25] Financial Management - **R&D Investment**: Projected **$6 billion** in R&D expenses for 2026, focusing on late-stage programs [10] - **Tax Rate**: Expected to remain in the mid-teens range, influenced by stock-based compensation [11] - **Cash Reserves**: Approximately **$19 billion** in cash, with plans for strategic investments and share repurchases [50][52] Intellectual Property and Lifecycle Management - **DUPIXENT IP**: Composition of matter patent expires in **2031** in the U.S., with additional patents extending into the **2040s** [21][22] - **Lifecycle Management**: Plans for next-generation products to extend the DUPIXENT franchise, including long-acting formulations [22][24] Charitable Contributions - **Funding Initiatives**: Announced a **$200 million** matching program for charitable contributions in 2026 to support patient access to therapies [15][16] Market Challenges - **Injection Trends**: A **12%** year-over-year decrease in branded injections, with an increase in Avastin usage, indicating competitive pressures [17][18] Conclusion - **Underappreciated Aspects**: The investment in the Regeneron Genetics Center, with **3 million exomes sequenced**, is seen as a competitive advantage for future developments [55][56]

Core Insights - Apogee Therapeutics is advancing its clinical pipeline, particularly zumilokibart (APG777), with significant milestones expected in atopic dermatitis (AD) and other indications [1][2][3] Pipeline Progress - APEX Phase 2 Part A 52-week data for zumilokibart is expected this month, while Part B 16-week data is anticipated in Q2 2026 [1][3] - Phase 3 trial initiation for zumilokibart in AD is targeted for the second half of 2026 [1][3] - Positive interim results from the Phase 1b trial in asthma support the potential for zumilokibart in multiple indications, with further details to be shared later this year [1][3] Financial Position - As of December 31, 2025, the company reported a strong cash position of $902.9 million, up from $731.1 million in 2024, providing a runway into the second half of 2028 [7] - Research and development (R&D) expenses increased to $214.7 million in 2025 from $167.9 million in 2024, driven by pipeline advancement and personnel-related costs [7] - General and administrative (G&A) expenses rose to $70.9 million in 2025 from $49.0 million in 2024, reflecting increased headcount and equity-based compensation [7] Market Strategy - The company aims to position zumilokibart as a "pipeline-in-a-product," with plans to expand its indications to asthma and eosinophilic esophagitis (EoE) [2][3] - A head-to-head trial of APG279 (zumilokibart + APG990) against DUPIXENT is ongoing, with interim data expected in the second half of 2026 [1][3]

Core Insights - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has shown steady revenue growth, with a 3% increase in fourth-quarter sales compared to the previous year, driven by double-digit growth in three key products [2][3] Sales Performance - Global net sales of DUPIXENT increased by 32%, while LIBTAYO sales rose by 13% on a constant-currency basis [3] - In the U.S., EYLEA HD sales surged by 66%, indicating strong momentum in the domestic market [3] Product Highlights - DUPIXENT is described as a core pillar of Regeneron's business, currently used by over 1.4 million patients worldwide, with further growth anticipated [4] - LIBTAYO has shown progress, particularly in adjuvant CSCC and gaining market share in advanced non-small cell lung cancer, becoming the second most prescribed immunotherapy in the first-line setting in the U.S. [4] Future Outlook - The company has a busy regulatory and development agenda, expecting at least four FDA approvals, including three new molecular entities and the EYLEA HD prefilled syringe [5] - Plans include launching 18 additional Phase III studies over the coming years, with an estimated total enrollment of about 35,000 patients, aimed at supporting the next wave of potential blockbuster products [5]

Core Insights - Longleaf Partners Fund returned 3.35% in Q4 2025, outperforming the S&P 500's 2.66% but underperforming the Russell 1000 Value Index's 3.81% [1] - The firm faced challenges in 2025, with only 5% of the portfolio gaining 20% or more compared to 35% of the S&P 500 [1] - The firm emphasizes strengthening portfolio outcomes over chasing short-term winners, advocating for a focus on real companies during speculative periods [1] Company Focus: Regeneron Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. had a one-month return of -5.94% and a 52-week gain of 7.55%, with a market capitalization of $77.693 billion [2] - Initially a detractor, Regeneron became a contributor in Q4 2025, with a phased buy-in strategy proving effective [3] - The company is well-positioned in allergic diseases and oncology, with a focus on its pipeline value rather than just EYLEA, which constitutes less than 20% of its value [3] - Regeneron has a net cash balance sheet, strong owner-partners, and has avoided large M&A, opting for significant share repurchases in 2025 [3]

Financial Data and Key Metrics Changes - Company revenue increased from EUR 33 billion to approximately EUR 45 billion since 2019, reflecting significant growth [2] - The workforce reduced from 118,000 in 2019 to around 72,000, indicating a strategic shift towards modernization [2] - Manufacturing sites decreased from over 70 to 38, showcasing efforts to streamline operations [2] - In Q3, the company reported an 8.8% growth in top-line revenue, 9.7% growth in BOI, and 12.4% growth in EPS, with a 10.2% growth excluding buybacks [17][18] Business Line Data and Key Metrics Changes - DUPIXENT experienced a 26% growth in Q3, demonstrating strong commercial capabilities despite competitive threats [3] - The company is focusing on advancing its pipeline, with several drugs in various stages of development, including tolebrutinib and amlitelimab [4][5] Market Data and Key Metrics Changes - The U.S. market is projected to face loss of exclusivity (LOE) for DUPIXENT in 2031, while Europe is expected to follow in 2033 [3] - The company anticipates significant growth opportunities in specialty care, which is becoming a larger part of its portfolio [17] Company Strategy and Development Direction - The company aims to transform into an R&D-led pharmaceutical entity, having exited the consumer health sector [2] - There is a commitment to enhancing the internal pipeline, with a recognition that the current number of preclinical and phase I programs is insufficient compared to peers [5] - The acquisition of Blueprint is seen as a strategic move to support top-line growth through the DUPIXENT LOE period [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to commercialize new drugs effectively, despite challenges in R&D [3][4] - There is a cautious outlook for 2027, primarily due to the anticipated loss of R&D offsets from Regeneron [15] - The company is focused on maintaining efficiency while investing in R&D, with a goal to deliver attractive financials alongside growth [17][18] Other Important Information - The company is actively pruning its R&D portfolio to focus on high-value indications, which is expected to enhance overall efficiency [43] - Management highlighted the importance of understanding patient populations and treatment paradigms in immunology to drive future success [59][70] Q&A Session Summary Question: How is the company planning to navigate the LOE in 2031? - The company has a robust pipeline and several patents that will support its strategy post-LOE, with plans to launch new medicines [3] Question: What is the mix between internal pipeline and M&A? - The company acknowledges a need for additional high-quality programs and is actively looking for opportunities to enhance its pipeline [5] Question: How does the company view margin progression? - Management indicated that while there are challenges, the transition to a specialty care-led portfolio is expected to improve efficiency and margins [17] Question: What are the expectations for DUPIXENT's growth? - Management remains optimistic about DUPIXENT's growth trajectory, projecting it to reach EUR 22 billion by 2030 [71] Question: How does the company plan to address the competitive landscape in immunology? - The company believes that multiple treatment options will benefit the market, and it is focused on ensuring its products meet the needs of patients effectively [157][166]

Regeneron Pharmaceuticals FY Conference Summary Company Overview - **Company**: Regeneron Pharmaceuticals (NasdaqGS:REGN) - **Date of Conference**: September 24, 2025 Key Points Commercial Performance - **EYLEA HD Performance**: - 5% sequential growth in demand in Q1 and 16% in Q2 attributed to effective commercial execution and physician-patient education [4][5] - Demand is expected to increase further once headwinds are resolved, particularly regarding reimbursement and prefilled syringe preferences [5][6] - Upcoming PDUFA dates: late October for prefilled syringe and late November for RVO and Q4 dosing [8] Pipeline Developments - **DUPIXENT**: - Strong performance across all eight approved indications, with ongoing growth in established indications like asthma and new launches in COPD, CSU, and bullous pemphigoid [15][16] - 70% of top-tier pulmonologists have prescribed DUPIXENT for COPD, indicating positive reception [18] - Strategic focus on lifecycle opportunities and adjacent type 2 pathways to maintain growth post-DUPIXENT exclusivity expiration in 2031 [21][23] - **Oncology Pipeline**: - Recent approvals for bispecifics, with a focus on Linezyth for multiple myeloma [24] - Plans to launch studies in earlier lines of treatment, combining Linezyth with carfilzomib, expected by the end of 2025 [26][28] - **Complement and Factor XI Programs**: - Promising data in myasthenia gravis (MG) with a focus on quarterly dosing advantages [35] - Factor XI program aims to reduce bleeding risks associated with anticoagulants, with ongoing Phase 3 studies [39][40] R&D and Capital Allocation - **R&D Investment Strategy**: - Focus on internal R&D as a primary capital allocation priority, with a robust pipeline driving long-term shareholder value [50][52] - Share repurchase program and dividend implementation to enhance shareholder returns [51] - **External Innovation**: - Active exploration of licensing and collaboration opportunities, though M&A remains a secondary focus [50][55] Market Outlook and Strategic Vision - **Pipeline Potential**: - The breadth and depth of the pipeline are viewed as unprecedented, with confidence in the ability to drive future growth [57][58] - Ongoing preclinical opportunities in various therapeutic areas, including genetics and rare diseases, are expected to yield significant advancements [59] Regulatory and Competitive Landscape - **Biosimilars Impact**: - Gradual uptake of existing biosimilars noted, with potential for increased pricing pressure as more entrants are expected in 2026 [11][12] - **DTC Advertising Restrictions**: - Generalized communication from the administration regarding DTC advertising, with no specific implications for Regeneron noted [19] Conclusion - Regeneron Pharmaceuticals is positioned for continued growth through its strong product pipeline, strategic R&D investments, and proactive market engagement. The company remains focused on addressing competitive pressures while leveraging its innovative capabilities to enhance patient outcomes and shareholder value.

Financial Data and Key Metrics Changes - Regeneron reported a strong quarter with EYLEA HD showing the strongest growth in the branded category within the anti-VEGF category, with demand growth of approximately 16% in the quarter compared to 5% in the previous quarter [7][12] - The overall franchise performance of EYLEA and EYLEA HD accounts for 60% of the anti-VEGF branded category, indicating a stable growth trajectory [25] Business Line Data and Key Metrics Changes - EYLEA HD has been in the market for about two years and is less impacted by affordability challenges compared to EYLEA, which is a larger product [15][21] - The introduction of a prefilled syringe for EYLEA HD is expected to enhance convenience for busy retina practices, which treat many patients daily [10][33] Market Data and Key Metrics Changes - The market for EYLEA HD is complicated, with affordability issues affecting the branded category due to high out-of-pocket costs for patients on Medicare plans [12][21] - Regeneron has launched a program to match donations to help patients offset these costs, although contributions have been lower than in previous years [12][13] Company Strategy and Development Direction - Regeneron aims to broaden the label for EYLEA HD, including potential enhancements such as Q4 weekly dosing and the RVO indication, which was a $1 billion indication for EYLEA in 2024 [11][34] - The company is focused on maintaining competitive readiness across its product lines, particularly with DUPIXENT, which continues to grow despite increasing competition [46][61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of EYLEA HD and DUPIXENT, highlighting the importance of upcoming regulatory approvals and market expansions [41][86] - The company is actively working on resolving manufacturing issues with its partner, Catalent, to ensure timely FDA approvals for new product submissions [35][36] Other Important Information - Regeneron is exploring additional indications for its C5 franchise, with ongoing studies in myasthenia gravis and geographic atrophy, indicating a strong pipeline for future growth [70] - The company is also considering a potential third Phase III study for itapacumab, pending discussions with regulatory authorities [76] Q&A Session Summary Question: How has the strength of high dose EYLEA been impacted by charity contributions? - Management indicated that the strength seen in high dose EYLEA is primarily due to the product's performance rather than charity contributions, which have not yet significantly impacted sales [14][15] Question: How is Regeneron addressing competition from biosimilars? - Management noted that while there is selective interest in biosimilars, many practices prefer EYLEA and EYLEA HD due to their established efficacy and safety profiles [27][30] Question: What are the expectations for upcoming PDUFAs? - Management confirmed that all submissions for Q4 dosing, RVO, and prefilled syringe approvals have been delayed due to manufacturing issues, but they remain confident in the outcomes once resolved [35][40] Question: What is the growth outlook for DUPIXENT? - Management highlighted that DUPIXENT continues to grow at over 20%, with multiple indications contributing to its success, and they expect this trend to continue [43][46] Question: How does Regeneron plan to position its new product in a crowded market? - Management expressed excitement about the clinical data for their new product and emphasized the importance of efficacy and convenience in positioning against competitors [63][64]